June 5, 2020
PA-20-135 - Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)
National Institute on Drug Abuse (NIDA)
The purpose of this Notice is to inform potential applicants that the National institute of Drug Abuse (NIDA) will participate, effective immediately, in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)".
The following changes have been made to reflect NIDA’s participation in this FOA. The changes are in italics.:
Part 1. Overview Information
Components of Participating Organizations
National Cancer Institute (NCI)
National Center for Complementary and Integrative Health (NCCIH)
National Human Genome Research Institute (NHGRI)
National Institute of Allergy and Infectious Diseases (NIAID)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Environmental Health Sciences (NIEHS)
National Institute of General Medical Sciences (NIGMS)
National Institute on Minority Health and Health Disparities (NIMHD)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Office of Strategic Coordination (Common Fund)
National Center for Advancing Translational Sciences (NCATS)
National Institute on Alcohol Abuse and Alcoholism (NIAAA National Institute on Drug Abuse (NIDA)
Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.213, 93.393, 93.394, 93.395, 93.396, 93.399, 93.172, 93.855, 93.865, 93.847, 93.113, 93.142, 93.143, 93.859, 93.307, 93.286, 93.350, 93.273, 93.310, 93.279
All other aspects of this FOA remain unchanged.
For any scientific or research-related questions on this emergency application notice please contact the Program Officer listed in the Emergency Notice of Special Interest (NOSI).